Back to News
Market Impact: 0.2
Craig-Hallum Initiates Coverage of TELA Bio at Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Craig-Hallum initiated coverage of TELA Bio (NASDAQGM: TELA) with a Buy rating on September 25, 2026. Shares closed at $1.28 that day, up $0.01, or roughly 0.8%, from the September 24 close of $1.27. The favorable initiation is a modest positive catalyst, though the reported immediate price move was limited.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
TELA0.45
More News
- Trump’s new Medicaid rules will kick in, and GOP states are tougher. Someone may be too frail to work but can’t afford to see a doctor to prove it
- Insurers claim AI is already increasing healthcare costs
- Hershey Trust Co. sells $5.05 million in Hershey Co. stock
- ‘Godfather of AI’ explains how humanity could end: Even without a bad actor, AI ‘may derive subgoals that cause it to want to get rid of people’
- Supply glut, lab-grown alternatives: What's behind the fall of diamond prices to record lows
- White House moves to block $810 million in funding through pocket rescission
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Search Earnings Call Transcripts With AI
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI